Nadecnemab

The primary objective of the study is to evaluate the efficacy of REGN5069 compared to placebo in patients with pain due to radiographically-confirmed OA of the knee who have a history of inadequate joint pain relief or intolerance to current analgesic therapy.
The secondary objectives of the study are:
To characterize the concentrations of functional REGN5069 in serum over time when patients are treated for up to 12 weeks
To assess the safety and tolerability of REGN5069 compared with placebo when patients are treated for up to 12 weeks
To measure levels of anti-drug antibodies (ADAs) against REGN5069 following multiple IV administrations

The primary objective of the study is to evaluate the safety and tolerability of single ascending doses of REGN5069 administered intravenously (IV) and subcutaneously (SC) in healthy male and female participants.
The secondary objectives of the study are to characterize the pharmacokinetics (PK) profile of single IV and SC doses of REGN5069 in healthy participants and assess the immunogenicity of REGN5069 in healthy participants administered single IV or SC doses of REGN5069